Future implications for palliative therapy with selective immunomodulating microtubule binding agents as prevention against chemotherapy-induced neutropenia in high-risk patients with solid tumors.
EP. 1: CIN in Solid Tumors
General considerations surrounding the risk of chemotherapy-induced neutropenia in solid tumors.
EP. 2: CIN Prophylaxis in Solid Tumors
Considerations for treatment selection for chemotherapy-induced neutropenia.
EP. 3: CIN Severity and Management
Implications of severity and sequelae of chemotherapy-induced neutropenia for disease management.
EP. 4: Minimizing the Risk of CIN in the Curative Setting
Recommendations for preventing and mitigation infection risk in patients with chemotherapy-induced neutropenia in the adjuvant setting.
EP. 5: Treatment Options for CIN
Current mitigation and management strategies for chemotherapy-induced neutropenia.
EP. 6: Challenges Managing CIN
Limitations of current therapies available for the prevention and management of chemotherapy-induced neutropenia.
EP. 7: CIN and Metastatic Disease
Strategies for prophylaxis against chemotherapy-induced neutropenia in the setting of metastatic disease.
EP. 8: Plinabulin for CIN
The rationale for studying plinabulin, a first-in-class selective immunomodulating microtubule binding agent, for the prevention of chemotherapy-induced neutropenia.
EP. 9: PROTECTIVE Trials of Plinabulin in Solid Tumors
An overview of the Protective-1 trial of single-agent plinabulin vs pegfilgrastim after docetaxel in patients with advanced breast cancer, advanced non–small cell lung cancer, and hormone-refractory prostate cancer.
EP. 10: Plinabulin CIN Prophylaxis: Monotherapy Vs Combination Therapy
Implications for using plinabulin as prophylaxis against chemotherapy-induced neutropenia alone or in combination with other therapies based on data revealed by the Protective-1 and Protective-2 trials.
EP. 11: CIN Prophylaxis: Integrating Plinabulin into Clinical Practice
A discussion regarding patient selection and indications for using plinabulin, a first-in-class selective immunomodulating microtubule-binding agent, as prophylaxis against chemotherapy-induced neutropenia.
EP. 12: Advances in the Prevention of CIN
Unmet needs and future directions in the prevention and management of chemotherapy-induced neutropenia.
2 Commerce Drive Cranbury, NJ 08512